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the former. My editorial highlighted the
latter. Cardioversions are often done within
7 days or even 24 h from the onset of AF.
Some of these episodes of AF will indeed
be long-lasting (persistent AF) but some
would be short-term and would self-termi-
nate if allowed to do so (paroxysmal AF).
The Guidelines committee recognized the
problem and chose a pragmatic but arbitrary
approach, calling for all of these to be
classiﬁed as episodes of persistent AF.1 The
AF Guidelines are currently being re-written
but the classiﬁcation scheme is unaltered.
Any modiﬁcations to the current scheme
should be simple, practical, and evidence-
based, if possible. To modify the scheme a
wide consensus should be sought and the
imprimatur of professional organizations,
such as the European Cardiac Society,
American Heart Association, American
College of Cardiology, Heart Rhythm Society,
and others would be highly desirable.
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Normal range of N-terminal pro-brain
natriuretic peptide: a note of caution
With interest we read the article by Galasko
et al.1 in a recent issue. The authors present
age- and gender-stratiﬁed normal values for
N-terminal pro-brain natriuretic peptide
(NTpBNP), which they validated in subjects
with high risk for cardiovascular disease
recruited from community practices and in a
random sample of low-risk subjects without
cardiovascular risk factors. In this study,
the deﬁnition of signiﬁcant cardiovascular
diseasewas based on a history of cardiovascu-
lar risk factors and coronary artery disease
(CAD) aswell as pathologic echocardiographic
ﬁndings. However, the authors’ conclusion
that the cut-off values provided offer excel-
lent negative and positive predictive values
for ruling in or out cardiovascular disease
should be taken with caution. Signiﬁcant
cardiovascular disease cannot be ruled out
by these cut-off values, because Galasko
et al. did not reliably rule out silent CAD in
the subjects assessed. Especially for groups
with higher prevalence of CAD, as in older
subjects, or with a higher rate of silent CAD,
as in women, the cut-off values given might
be too high. NTpBNP has been shown to be
elevated in patients with CAD,2 and elevated
levels are associated with adverse out-
comes.3 Unless CAD is not excluded by an
accurate diagnostic reference method, i.e.
coronary angiography, subjects with silent
but signiﬁcant CAD will be misclassiﬁed as
free of signiﬁcant cardiovascular disease. In
the paper addressed, NTpBNP levels of
subjects with silent CAD might have been
included in the calculation of the upper
limit of the normal range of NTpBNP. The
upper limit of the normal range of NTpBNP
might therefore be lower than that stated in
the study of Galasko et al.
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Normal range of N-terminal pro-brain
natriuretic peptide: a note of caution:
reply
We would like to answer to Wolber and
Maeder’s comments in turn.
They state that our conclusions must be
taken with caution, as silent coronary artery
disease (CAD) was not ruled out. There is,
however, no evidence that screening for
silent CAD even by coronary angiography pro-
duces prognostic beneﬁt, so we were entitled
not to assess this, sticking to conditions
where early screening may be beneﬁcial.
Moreover, our conclusions stated that
normal NTpBNP levels ruled out many signiﬁ-
cant cardiovascular conditions, not cardio-
vascular disease in general as they suggest.
They are similarly concerned that the
developed NTpBNP upper reference values
may be too high as subjects with silent CAD
could have been included in the normal
group, recommending diagnostic angiography
in these subjects. Certainly, we tried to make
this group as normal as possible, excluding
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